See the DrugPatentWatch profile for cosentyx

Starting Dose for Cosentyx in PsA: A Comprehensive Guide

What is Psoriatic Arthritis?

Psoriatic arthritis (PsA) is a chronic autoimmune disease that affects approximately 30% of people with psoriasis. It is characterized by inflammation in the joints, which can lead to pain, stiffness, and swelling. PsA can also cause inflammation in other parts of the body, such as the skin, nails, and eyes.

What is Cosentyx?

Cosentyx is a biologic medication used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It is a human interleukin-17A antagonist that works by blocking the action of IL-17A, a protein that plays a key role in the inflammatory process.

Starting Dose for Cosentyx in PsA

The starting dose for Cosentyx in PsA is 100 mg every week, administered subcutaneously (under the skin). This dose can be adjusted based on the patient's response to treatment.

Indications and Limitations

Cosentyx is approved for the treatment of PsA in adults who have had an inadequate response to previous treatments. It is also approved for the treatment of moderate to severe plaque psoriasis and ankylosing spondylitis.

Dosage Adjustments

The dosage of Cosentyx may need to be adjusted based on the patient's response to treatment. If the patient's symptoms do not improve after 12 weeks of treatment, the dose may be increased to 200 mg every week.

Contraindications

Cosentyx is contraindicated in patients with a history of hypersensitivity to the active substance or any of the excipients. It is also contraindicated in patients with active tuberculosis or a history of tuberculosis.

Adverse Reactions

Common adverse reactions to Cosentyx include:

* Injection site reactions
* Headache
* Fatigue
* Nasopharyngitis
* Upper respiratory tract infection

Special Populations

The safety and efficacy of Cosentyx in pediatric patients have not been established. It is also not recommended for use in patients with severe hepatic impairment.

Pregnancy and Lactation

There are limited data on the use of Cosentyx during pregnancy and lactation. It is recommended to avoid using Cosentyx during pregnancy and lactation unless the potential benefit justifies the potential risk.

Conclusion

Cosentyx is a biologic medication used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. The starting dose for Cosentyx in PsA is 100 mg every week, administered subcutaneously. The dosage may need to be adjusted based on the patient's response to treatment. It is important to weigh the potential benefits and risks of Cosentyx and to discuss any concerns with a healthcare provider.

FAQs

1. What is the starting dose for Cosentyx in PsA?

The starting dose for Cosentyx in PsA is 100 mg every week, administered subcutaneously.

2. How often is Cosentyx administered?

Cosentyx is administered every week, subcutaneously.

3. What are the common adverse reactions to Cosentyx?

Common adverse reactions to Cosentyx include injection site reactions, headache, fatigue, nasopharyngitis, and upper respiratory tract infection.

4. Is Cosentyx safe for use during pregnancy and lactation?

There are limited data on the use of Cosentyx during pregnancy and lactation. It is recommended to avoid using Cosentyx during pregnancy and lactation unless the potential benefit justifies the potential risk.

5. Can the dosage of Cosentyx be adjusted?

Yes, the dosage of Cosentyx may need to be adjusted based on the patient's response to treatment.

Cited Sources

1. DrugPatentWatch.com. (2022). Cosentyx (Secukinumab) Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent/US-9315151>

Additional Sources

1. National Psoriasis Foundation. (n.d.). Psoriatic Arthritis. Retrieved from <https://www.psoriasis.org/psoriatic-arthritis/>
2. U.S. Food and Drug Administration. (2022). Cosentyx (Secukinumab) Injection. Retrieved from <https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125553s114lbl.pdf>
3. European Medicines Agency. (2022). Cosentyx (Secukinumab). Retrieved from <https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx>